FPR2 agonists, such as compound 17b, BMS-986235, and WKYMVm, have demonstrated reparative activity and reduced immune dysregulation in experimental models of myocardial infarction (MI) and HF [297–300]. The gene discussed is FPR2; the disease is myocardial infarction.